TP53 mutations are associated with primary endocrine resistance in luminal early breast cancer

Abstract Background Whereas the genomic landscape of endocrine‐resistant breast cancer has been intensely characterized in previously treated cases with local or distant recurrence, comparably little is known about genomic alterations conveying primary non‐responsiveness to endocrine treatment in lu...

Description complète

Enregistré dans:

Détails bibliographiques
Auteurs principaux:	Isabel Grote, Stephan Bartels, Leonie Kandt, Laura Bollmann, Henriette Christgen, Malte Gronewold, Mieke Raap, Ulrich Lehmann, Oleg Gluz, Ulrike Nitz, Sherko Kuemmel, Christine zuEulenburg, Michael Braun, Bahriye Aktas, Eva‐Maria Grischke, Claudia Schumacher, Kerstin Luedtke‐Heckenkamp, Ronald Kates, Rachel Wuerstlein, Monika Graeser, Nadia Harbeck, Matthias Christgen, Hans Kreipe
Format:	article
Langue:	EN
Publié:	Wiley 2021
Sujets:	breast cancer endocrine proliferative response Ki67 preoperative endocrine therapy TP53 Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
Accès en ligne:	https://doaj.org/article/2c544d649b024c5bbd721b91d7f7c740
Tags:	Ajouter un tag Pas de tags, Soyez le premier à ajouter un tag!

Soyez le premier à ajouter un commentaire!

TP53 mutations are associated with primary endocrine resistance in luminal early breast cancer

Documents similaires